Daniel A. Axelrad

researcher

Daniel A. Axelrad is …
instance of (P31):
humanQ5

External links are
P496ORCID iD0000-0003-2814-2601
P1153Scopus author ID6603759014

P735given nameDanielQ14516546
DanielQ14516546
P106occupationresearcherQ1650915
P21sex or gendermaleQ6581097

Reverse relations

author (P50)
Q28384631Adverse effects in risk assessment: modeling polychlorinated biphenyls and thyroid hormone disruption outcomes in animals and humans
Q44772303An analysis of candidates for addition to the Clean Air Act list of hazardous air pollutants.
Q74503573Application of health information to hazardous air pollutants modeled in EPA's Cumulative Exposure Project
Q64967753Beyond the RfD: Broad Application of a Probabilistic Approach to Improve Chemical Dose-Response Assessments for Noncancer Effects.
Q36444999Blood Lead and Other Metal Biomarkers as Risk Factors for Cardiovascular Disease Mortality
Q33733831Calculating summary statistics for population chemical biomonitoring in women of childbearing age with adjustment for age-specific natality.
Q53285267Chemical Risk Assessment: Traditional vs Public Health Perspectives.
Q46019996Developmental PBDE Exposure and IQ/ADHD in Childhood: A Systematic Review and Meta-analysis.
Q31110059Dose-response relationship of prenatal mercury exposure and IQ: an integrative analysis of epidemiologic data
Q53412818Estimating cancer risk from outdoor concentrations of hazardous air pollutants in 1990.
Q35745086Estimating risk from ambient concentrations of acrolein across the United States.
Q46358388Estimating the health benefits of environmental regulations.
Q28392774Evaluating cumulative organophosphorus pesticide body burden of children: a national case study
Q25256912Integrated assessment of environment and health: America's children and the environment.
Q35802381Linking economics and risk assessment.
Q34478465Meeting report: Estimating the benefits of reducing hazardous air pollutants--summary of 2009 workshop and future considerations
Q23922961Meeting report: moving upstream-evaluating adverse upstream end points for improved risk assessment and decision-making
Q92565779Methods for evaluating variability in human health dose-response characterization
Q43984248National Estimates of Outdoor Air Toxics Concentrations
Q33413534PCB body burdens in US women of childbearing age 2001-2002: An evaluation of alternate summary metrics of NHANES data.
Q90739764Preterm birth and economic benefits of reduced maternal exposure to fine particulate matter
Q33219529Risk assessment for benefits analysis: framework for analysis of a thyroid-disrupting chemical
Q34275367The Navigation Guide - evidence-based medicine meets environmental health: integration of animal and human evidence for PFOA effects on fetal growth.
Q26851809The Navigation Guide - evidence-based medicine meets environmental health: systematic review of human evidence for PFOA effects on fetal growth
Q34275308The Navigation Guide - evidence-based medicine meets environmental health: systematic review of nonhuman evidence for PFOA effects on fetal growth
Q113857146Toxic Substances Control Act (TSCA) Implementation: How the Amended Law Has Failed to Protect Vulnerable Populations from Toxic Chemicals in the United States